Dice CEO: Energy, T...
Health Care: Drugs
Alexza Pharmaceuticals Inc. (ALXA: NASDAQ)
$0.36 0.00 | -1.37%
06/01/12 - 04:00 PM ET
Ratio Comparisons
| Company | Industry | S&P 500 | |
| Valuation Ratios | |||
|---|---|---|---|
| P/E Ratio (TTM) | n.a. | 28.50 | 17.70 |
| P/E High - Last 5 Yrs | n.a. | 189.00 | 67.70 |
| P/E Low - Last 5 Yrs | n.a. | 18.60 | 12.50 |
| Beta | 1.70 | 0.62 | 0.98 |
| Price to Sales (TTM) | 6.79 | 4.29 | 1.42 |
| Price to Book (MRQ) | 4.83 | 4.39 | 2.41 |
| Price to Tangible Book (MRQ) | 4.83 | 14.20 | 5.08 |
| Price to Cash Flow (TTM) | -1.40 | 19.50 | 9.80 |
| Price to Free Cash Flow (TTM) | -1.70 | -327.00 | 17.40 |
| Dividends | |||
| Dividend Yield (%) | 0.00 | 0.90 | 2.10 |
| Dividend Yield - 5 Yr Avg (%) | n.a. | 0.80 | 2.20 |
| Dividend 5 Yr Growth Rate (%) | n.a. | 42.32 | -0.76 |
| Payout Ratio (TTM) | 0.00 | 51.00 | 30.00 |
| Sales (MRQ) vs Qtr 1 Yr Ago (%) | 49.60 | 15.60 | 11.80 |
| Sales (TTM) vs TTM 1 Yr Ago (%) | -86.80 | 9.00 | 9.20 |
| Growth Rates (%) | |||
| Sales - 5 Yr Growth Rate (%) | n.a. | 6.32 | 1.79 |
| EPS (MRQ) vs Qtr 1 Yr Ago (%) | n.a. | -2.50 | 17.50 |
| EPS (TTM) vs TTM 1 Yr Ago (%) | n.a. | -2.50 | 17.50 |
| EPS - 5 Yr Growth Rate (%) | n.a. | 24.63 | -1.66 |
| Capital Spending - 5 Yr Growth Rate (%) | -38.42 | -6.43 | -1.17 |
| Financial Strength | |||
| Quick Ratio (MRQ) | 1.00 | 1.30 | 1.10 |
| Current Ratio (MRQ) | 1.40 | 1.80 | 1.60 |
| LT Debt to Equity (MRQ) | 0.00 | 0.29 | 0.82 |
| Total Debt to Equity (MRQ) | 1.23 | 0.37 | 0.96 |
| Interest Coverage (TTM) | n.a. | 9.20 | 5.50 |
| Profitability Ratios (%) | |||
| Gross Margin (TTM) | n.a. | 75.60 | 46.90 |
| Gross Margin - 5 Yr Avg | n.a. | 75.30 | 47.70 |
| EBITD Margin (TTM) | n.a. | 29.40 | 18.90 |
| EBITD - 5 Yr Avg | -447.84 | 0.00 | 0.00 |
| Pre-Tax Margin (TTM) | n.a. | 18.00 | 12.10 |
| Pre-Tax Margin - 5 Yr Avg | n.a. | 11.80 | 10.30 |
| Management Effectiveness (%) | |||
| Net Profit Margin (TTM) | -5.72 | 0.14 | 0.09 |
| Net Profit Margin - 5 Yr Avg | n.a. | 8.60 | 7.00 |
| Return on Assets (TTM) | -66.60 | 7.30 | 3.10 |
| Return on Assets - 5 Yr Avg | -62.80 | 4.60 | 2.50 |
| Return on Investment (TTM) | -406.00 | 10.40 | 7.90 |
| Return on Investment - 5 Yr Avg | -218.00 | 6.50 | 6.50 |
| Efficiency | |||
| Revenue/Employee (TTM) | 142,841.00 | 404,888.00 | 449,376.00 |
| Net Income/Employee (TTM) | -816,886.00 | 57,122.00 | 39,003.00 |
| Receivable Turnover (TTM) | n.a. | 4.70 | 7.60 |
| Inventory Turnover (TTM) | n.a. | 1.70 | 8.30 |
| Asset Turnover (TTM) | 0.10 | 0.60 | 0.40 |
Portfolios with ALXA
- Portfolio NameUser Type
- Uservlady 1
- ContributorStocks With Big Insider Buy...
- UserSMITTY
- ContributorBarron's Insider Purchases ...
- UserHi Potential
- UserRAPTOR SPRTD RED-03110081643
- UserScottrade 20K
- UserBburn Portfolio 1
- UserRatBastard Portfolio 1
- Userpornholio
Latest ALXA Headlines from TheStreet
- Friday's Top 10 Articles, Videos on TheStreet 05.04.12 | 01:05 pm
- Alexza Stock Gaps Down On Today's Open (ALXA) 05.04.12 | 09:05 am
- Biotech Stock Mailbag: Exelixis, Protalix, Arena 05.04.12 | 07:05 am
- 26 Drugs Facing FDA Approval in 2012 05.02.12 | 01:05 pm
- The Next Big Thing In Biotech: Alexza
04.13.12 | 06:04 am - Alexza Pharmaceuticals Inc. Stock Downgraded (ALXA) 02.24.12 | 05:02 am
- Alexza Stock Gaps Down On Today's Open (ALXA) 02.17.12 | 08:02 am
- 5 Stocks Insiders Are Loading Up On 01.26.12 | 12:01 pm
- Alexza Stock Gaps Up On Today's Open (ALXA) 01.03.12 | 11:01 am
- Biotech Stock Live Chat: 2012 Preview 12.15.11 | 11:12 am
Press Releases for ALXA
- Bronstein, Gewirtz & Grossman, LLC Announces Investigation Of Alexza Pharmaceuticals Inc. - PR Newswire 05.07.12 | 08:05 am
- Alexza And Grupo Ferrer Amend Adasuve⢠Partnership - PR Newswire 03.07.12 | 04:03 pm
- Alexza To Announce 2011 Year-End Financial Results On Monday, March 12, 2012 - PR Newswire 03.05.12 | 09:03 am
- Alexza Prices $22 Million Public Offering - PR Newswire 02.17.12 | 07:02 am
- Alexza Announces Proposed Public Offering Of Common Stock And Warrants - PR Newswire 02.16.12 | 06:02 pm
- Alexza Pharmaceuticals Receives Day 80 Assessment Report For ADASUVE (Staccato® Loxapine) MAA - PR Newswire 02.13.12 | 08:02 am
- Alexza Retains Lazard To Explore Strategic Options - PR Newswire 12.16.11 | 08:12 pm
- FDA Psychopharmacologic Drugs Advisory Committee Recommends Approval Of Alexza's ADASUVE⢠- PR Newswire 12.13.11 | 05:12 am
- Alexza Pharmaceuticals To Present At The Lazard Capital Markets 8th Annual Healthcare Conference - PR Newswire 11.02.11 | 09:11 am
- Alexza To Announce 2011 Third Quarter Financial Results On Monday, November 7, 2011 - PR Newswire 10.27.11 | 06:10 pm
Partner Headlines for ALXA
- Benzinga's Microcap Movers for Friday May 4, 2012 - Benzinga 05.05.12 | 12:05 pm
- 6 Biotech Stocks With Huge Potential In May - Seeking Alpha 04.11.12 | 08:04 am
- Earnings Expectations for the Week of March 12 (URBN, ROST) - Benzinga 03.11.12 | 11:03 am
- Alexza and Grupo Ferrer Amend Adasuve Partnership Alexza and Grupo Ferrer Amend Adasuve Partnership; Ferrer to Purchase 2.42M Shares of Alexza Common Stock for $1.24 per Share - Benzinga 03.07.12 | 04:03 pm
- Analysis Of Institutional 5% Ownership Filings On Tuesday And Wednesday - Seeking Alpha 01.05.12 | 08:01 am
- Microcap Movers for Friday December 9, 2011 - Benzinga 12.09.11 | 06:12 pm
- Q3 Micro-Cap Biotech Picks By The World's Largest Fund Managers - Seeking Alpha 12.08.11 | 09:12 am
- Company News for October 5, 2011 - Corporate Summary - Zacks 10.05.11 | 10:10 am
- Alexza Pharmaceuticals Nears Daily High; Ready to Breakout - Benzinga 09.07.11 | 01:09 pm
- Alexza Hopes New NDA Submission Will Relieve Agitation - Benzinga 08.17.11 | 01:08 pm
